心脏射频消融术治疗心房颤动对继发性三尖瓣反流影响的研究进展
Research Progress on the Effect of Radiofrequency Catheter Ablation in the Treatment of Atrial Fibrillation on Secondary Tricuspid Regurgitation
摘要: 心房颤动是临床最常见的心律失常类型,继发性三尖瓣反流作为其常见并发症,是心血管疾病领域中易被忽视且临床管理极具挑战性的问题,二者存在紧密的病理生理关联并形成恶性循环。心房颤动发作时心房丧失规律收缩功能,可诱发右心房重构和三尖瓣环扩张,进而引发房性继发性三尖瓣反流;而继发性三尖瓣反流会进一步增加心脏容量负荷,加剧心房重构,促进房颤的持续和发展。心脏射频消融术通过消除异常电信号传导路径,恢复窦性心律,可改善心肌的能量代谢和电生理特性,促进心肌的修复和心脏逆向重构,从而改善继发性三尖瓣反流程度。心脏射频消融术在改善心房颤动合并继发性三尖瓣反流患者的瓣膜反流、逆转右心重构方面发挥重要作用,为该类患者的临床诊疗提供了新的思路与有效干预手段。
Abstract: Atrial fibrillation (AF) is the most common type of arrhythmia in clinical practice. Secondary tricuspid regurgitation (STR), a common complication of AF, is an easily overlooked problem with great challenges in clinical management in the field of cardiovascular diseases. There is a close pathophysiological association between the two, forming a vicious cycle. During AF episodes, the atria lose their regular contractile function, which can induce right atrial remodeling and tricuspid annular dilatation, thereby triggering atrial secondary tricuspid regurgitation (A-STR). In turn, STR further increases cardiac volume load, exacerbates atrial remodeling, and promotes the persistence and progression of AF. Cardiac radiofrequency catheter ablation (RFCA) can improve myocardial energy metabolism and electrophysiological characteristics, promote myocardial repair and cardiac reverse remodeling by eliminating abnormal electrical signal conduction pathways and restoring sinus rhythm, thereby reducing the severity of STR. RFCA plays an important role in improving valvular regurgitation and reversing right ventricular remodeling in patients with AF complicated by STR, providing new ideas and effective intervention methods for the clinical diagnosis and treatment of such patients.
文章引用:吴璟瑜, 凌智瑜. 心脏射频消融术治疗心房颤动对继发性三尖瓣反流影响的研究进展[J]. 临床医学进展, 2026, 16(4): 3002-3008. https://doi.org/10.12677/acm.2026.1641558

参考文献

[1] Stark, B.A., DeCleene, N.K., Desai, E.C., Hsu, J.M., Johnson, C.O., Lara-Castor, L., et al. (2025) Global, Regional, and National Burden of Cardiovascular Diseases and Risk Factors in 204 Countries and Territories, 1990-2023. JACC, 86, 2167-2243. [Google Scholar] [CrossRef
[2] Otto, C.M., Nishimura, R.A., Bonow, R.O., Carabello, B.A., Erwin, J.P., Gentile, F., et al. (2021) 2020 ACC/AHA Guideline for the Management of Patients with Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 143, e72-e227. [Google Scholar] [CrossRef] [PubMed]
[3] Praz, F., et al. (2025) 2025 ESC/EACTS Guidelines for the Management of Valvular Heart Disease. European Heart Journal, 46, 4635-4736.
[4] Yamamoto, Y., Daimon, M., Nakanishi, K., Nakao, T., Hirokawa, M., Ishiwata, J., et al. (2022) Incidence of Atrial Functional Tricuspid Regurgitation and Its Correlation with Tricuspid Valvular Deformation in Patients with Persistent Atrial Fibrillation. Frontiers in Cardiovascular Medicine, 9, Article ID: 1023732. [Google Scholar] [CrossRef] [PubMed]
[5] Vîjan, A.E., Daha, I.C., Delcea, C., Bădilă, E. and Dan, G. (2022) Prognostic Impact of Severe Atrial Functional Tricuspid Regurgitation in Atrial Fibrillation Patients. Journal of Clinical Medicine, 11, Article No. 7145. [Google Scholar] [CrossRef] [PubMed]
[6] Pagnesi, M., Riccardi, M., Chiarito, M., Stolfo, D., Baldetti, L., Lombardi, C.M., et al. (2024) Characteristics and Outcomes of Patients with Tricuspid Regurgitation and Advanced Heart Failure. Journal of Cardiovascular Medicine, 25, 200-209. [Google Scholar] [CrossRef] [PubMed]
[7] Hahn, R.T. (2023) Tricuspid Regurgitation. New England Journal of Medicine, 388, 1876-1891. [Google Scholar] [CrossRef] [PubMed]
[8] Hahn, R.T., Badano, L.P., Bartko, P.E., Muraru, D., Maisano, F., Zamorano, J.L., et al. (2022) Tricuspid Regurgitation: Recent Advances in Understanding Pathophysiology, Severity Grading and Outcome. European Heart JournalCardiovascular Imaging, 23, 913-929. [Google Scholar] [CrossRef] [PubMed]
[9] Muraru, D., Badano, L.P., Hahn, R.T., Lang, R.M., Delgado, V., Wunderlich, N.C., et al. (2024) Atrial Secondary Tricuspid Regurgitation: Pathophysiology, Definition, Diagnosis, and Treatment. European Heart Journal, 45, 895-911. [Google Scholar] [CrossRef] [PubMed]
[10] Adamo, M., Chioncel, O., Pagnesi, M., Bayes-Genis, A., Abdelhamid, M., Anker, S.D., et al. (2024) Epidemiology, Pathophysiology, Diagnosis and Management of Chronic Right-Sided Heart Failure and Tricuspid Regurgitation. a Clinical Consensus Statement of the Heart Failure Association (HFA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC. European Journal of Heart Failure, 26, 18-33. [Google Scholar] [CrossRef] [PubMed]
[11] Naser, J.A., Castrichini, M., Ibrahim, H.H., Scott, C.G., Lin, G., Lee, E., et al. (2024) Secondary Tricuspid Regurgitation: Incidence, Types, and Outcomes in Atrial Fibrillation vs. Sinus Rhythm. European Heart Journal, 45, 2878-2890. [Google Scholar] [CrossRef] [PubMed]
[12] Sanusi, M., Vempati, R., Umashankar, D., Tarannum, S., Varma, Y., Mohammed, F., et al. (2025) Molecular Mechanisms of Atrial Fibrillation Recurrence after Successful Catheter Ablation. Cells, 15, Article No. 36. [Google Scholar] [CrossRef
[13] Patlolla, S.H., Schaff, H.V., Nishimura, R.A., Stulak, J.M., Chamberlain, A.M., Pislaru, S.V., et al. (2022) Incidence and Burden of Tricuspid Regurgitation in Patients with Atrial Fibrillation. Journal of the American College of Cardiology, 80, 2289-2298. [Google Scholar] [CrossRef] [PubMed]
[14] Nishiwaki, S., Watanabe, S., Yoneda, F., Tanaka, M., Aizawa, T., Yamagami, S., et al. (2022) Impact of Catheter Ablation on Functional Tricuspid Regurgitation in Patients with Atrial Fibrillation. Journal of Interventional Cardiac Electrophysiology, 66, 1441-1453. [Google Scholar] [CrossRef] [PubMed]
[15] Tan, J., Yang, M., Wang, H., Shen, C., Wu, M., Xu, H., et al. (2022) Moderate Heart Rate Reduction Promotes Cardiac Regeneration through Stimulation of the Metabolic Pattern Switch. Cell Reports, 38, Article ID: 110468. [Google Scholar] [CrossRef] [PubMed]
[16] Soulat-Dufour, L., Lang, S., Addetia, K., Ederhy, S., Adavane-Scheuble, S., Chauvet-Droit, M., et al. (2022) Restoring Sinus Rhythm Reverses Cardiac Remodeling and Reduces Valvular Regurgitation in Patients with Atrial Fibrillation. Journal of the American College of Cardiology, 79, 951-961. [Google Scholar] [CrossRef] [PubMed]
[17] Liu, W., Wang, A., Li, Q., Zhang, Q., Chen, S., Wei, Y., et al. (2025) Long-Term Outcome of Catheter Ablation in Patients with Persistent Atrial Fibrillation and Functional Tricuspid Regurgitation. Frontiers in Cardiovascular Medicine, 12, Article ID: 1600238. [Google Scholar] [CrossRef
[18] Cha, M.J., Lee, S.A., Cho, M.S., et al. (2023) Reduction of Moderate to Severe Tricuspid Regurgitation after Catheter Ablation for Atrial Fibrillation. Heart, 110, 523-530. [Google Scholar] [CrossRef] [PubMed]
[19] Barison, A., Timoteo, A.T., Liga, R., Borodzicz-Jazdzyk, S., El Messaoudi, S., Luong, C., et al. (2024) Cardiovascular Imaging Research and Innovation in 2023. European Heart JournalImaging Methods and Practice, 2, qyae029. [Google Scholar] [CrossRef] [PubMed]
[20] 潘文志, 宋光远, 刘先宝, 等. 三尖瓣反流经导管治疗的中国专家共识[J]. 中国介入心脏病学杂志, 2024, 32(10): 551-561.
[21] Rajiah, P.S., Reddy, P., Baliyan, V., Hedgire, S.S., Foley, T.A., Williamson, E.E., et al. (2023) Utility of CT and MRI in Tricuspid Valve Interventions. RadioGraphics, 43, e220153. [Google Scholar] [CrossRef] [PubMed]
[22] Latib, A., Grigioni, F. and Hahn, R.T. (2018) Tricuspid Regurgitation: What Is the Real Clinical Impact and How Often Should It Be Treated? EuroIntervention, 14, AB101-AB111. [Google Scholar] [CrossRef] [PubMed]
[23] Pype, L.L., Domenech-Ximenos, B., Paelinck, B.P., Sturkenboom, N. and Van De Heyning, C.M. (2024) Assessment of Tricuspid Regurgitation by Cardiac Magnetic Resonance Imaging: Current Role and Future Applications. Journal of Clinical Medicine, 13, Article No. 4481. [Google Scholar] [CrossRef] [PubMed]
[24] Zhang, B., Xu, H., Zhang, H., Liu, Q., Ye, Y., Hao, J., et al. (2020) Prognostic Value of N-Terminal pro-B-Type Natriuretic Peptide in Elderly Patients with Valvular Heart Disease. Journal of the American College of Cardiology, 75, 1659-1672. [Google Scholar] [CrossRef] [PubMed]
[25] Craiem, D., Moukarzel, J., Casciaro, M.E., Stipechi, V. and Guevara, E. (2025) Association between Obesity and Prevalence of Significant Regurgitant Valvular Heart Disease over Time: A Cohort Study. Obesity Research & Clinical Practice, 19, 130-137. [Google Scholar] [CrossRef] [PubMed]